Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention

O. C. El Helou, E. F. Berbari, B. D. Lahr, Jeanette E Eckel-Passow, Raymund R Razonable, Irene Gaw Sia, A. Virk, R. C. Walker, J. M. Steckelberg, W. R. Wilson, A. D. Hanssen, D. R. Osmon

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

The aim of this study was to evaluate the efficacy and safety of rifampin for Staphylococcus aureus (SA) or coagulase negative staphylococci (CNS) prosthetic joint infection (PJI) treated with debridement and retention (D/R). We calculated the treatment failure cumulative incidence (TF) of a cohort of 101 patients with SA or CNS PJI treated with D/R and antimicrobial therapy. The effect of the use of a rifampin-based regimen was evaluated. Cox proportional hazards regression evaluated the association between treatment and time-to-TF controlling for the propensity to treat with rifampin and temporal confounders. Seven percent (1/14) of the prospective rifampin-treated patients, 32% (10/31) of the historical rifampin-treated patients and 38% (21/56) of the historical non-rifampin treated patients developed TF. After controlling for the propensity to treat with rifampin and American Society of Anesthesia scores, patients in the prospective cohort had a lower risk of TF compared to patients in the historical cohort not treated with rifampin (HR 0.11; 95%CI 0.01-0.84). None (0/14) of the patients in the prospective study developed hepatotoxicity. The outcome of staphylococcal PJI treated with D/R and rifampin-based regimens was better when compared with a historical cohort treated without rifampin.

Original languageEnglish (US)
Pages (from-to)961-967
Number of pages7
JournalEuropean Journal of Clinical Microbiology and Infectious Diseases
Volume29
Issue number8
DOIs
StatePublished - Aug 2010

Fingerprint

Debridement
Rifampin
Joints
Safety
Infection
Coagulase
Staphylococcus
Staphylococcus aureus
Treatment Failure
Anesthesia
Prospective Studies
Incidence
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Medicine(all)

Cite this

Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. / El Helou, O. C.; Berbari, E. F.; Lahr, B. D.; Eckel-Passow, Jeanette E; Razonable, Raymund R; Sia, Irene Gaw; Virk, A.; Walker, R. C.; Steckelberg, J. M.; Wilson, W. R.; Hanssen, A. D.; Osmon, D. R.

In: European Journal of Clinical Microbiology and Infectious Diseases, Vol. 29, No. 8, 08.2010, p. 961-967.

Research output: Contribution to journalArticle

El Helou, O. C. ; Berbari, E. F. ; Lahr, B. D. ; Eckel-Passow, Jeanette E ; Razonable, Raymund R ; Sia, Irene Gaw ; Virk, A. ; Walker, R. C. ; Steckelberg, J. M. ; Wilson, W. R. ; Hanssen, A. D. ; Osmon, D. R. / Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. In: European Journal of Clinical Microbiology and Infectious Diseases. 2010 ; Vol. 29, No. 8. pp. 961-967.
@article{1d4eed49a98345c282ea7ec56f94a7c1,
title = "Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention",
abstract = "The aim of this study was to evaluate the efficacy and safety of rifampin for Staphylococcus aureus (SA) or coagulase negative staphylococci (CNS) prosthetic joint infection (PJI) treated with debridement and retention (D/R). We calculated the treatment failure cumulative incidence (TF) of a cohort of 101 patients with SA or CNS PJI treated with D/R and antimicrobial therapy. The effect of the use of a rifampin-based regimen was evaluated. Cox proportional hazards regression evaluated the association between treatment and time-to-TF controlling for the propensity to treat with rifampin and temporal confounders. Seven percent (1/14) of the prospective rifampin-treated patients, 32{\%} (10/31) of the historical rifampin-treated patients and 38{\%} (21/56) of the historical non-rifampin treated patients developed TF. After controlling for the propensity to treat with rifampin and American Society of Anesthesia scores, patients in the prospective cohort had a lower risk of TF compared to patients in the historical cohort not treated with rifampin (HR 0.11; 95{\%}CI 0.01-0.84). None (0/14) of the patients in the prospective study developed hepatotoxicity. The outcome of staphylococcal PJI treated with D/R and rifampin-based regimens was better when compared with a historical cohort treated without rifampin.",
author = "{El Helou}, {O. C.} and Berbari, {E. F.} and Lahr, {B. D.} and Eckel-Passow, {Jeanette E} and Razonable, {Raymund R} and Sia, {Irene Gaw} and A. Virk and Walker, {R. C.} and Steckelberg, {J. M.} and Wilson, {W. R.} and Hanssen, {A. D.} and Osmon, {D. R.}",
year = "2010",
month = "8",
doi = "10.1007/s10096-010-0952-9",
language = "English (US)",
volume = "29",
pages = "961--967",
journal = "European Journal of Clinical Microbiology and Infectious Diseases",
issn = "0934-9723",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention

AU - El Helou, O. C.

AU - Berbari, E. F.

AU - Lahr, B. D.

AU - Eckel-Passow, Jeanette E

AU - Razonable, Raymund R

AU - Sia, Irene Gaw

AU - Virk, A.

AU - Walker, R. C.

AU - Steckelberg, J. M.

AU - Wilson, W. R.

AU - Hanssen, A. D.

AU - Osmon, D. R.

PY - 2010/8

Y1 - 2010/8

N2 - The aim of this study was to evaluate the efficacy and safety of rifampin for Staphylococcus aureus (SA) or coagulase negative staphylococci (CNS) prosthetic joint infection (PJI) treated with debridement and retention (D/R). We calculated the treatment failure cumulative incidence (TF) of a cohort of 101 patients with SA or CNS PJI treated with D/R and antimicrobial therapy. The effect of the use of a rifampin-based regimen was evaluated. Cox proportional hazards regression evaluated the association between treatment and time-to-TF controlling for the propensity to treat with rifampin and temporal confounders. Seven percent (1/14) of the prospective rifampin-treated patients, 32% (10/31) of the historical rifampin-treated patients and 38% (21/56) of the historical non-rifampin treated patients developed TF. After controlling for the propensity to treat with rifampin and American Society of Anesthesia scores, patients in the prospective cohort had a lower risk of TF compared to patients in the historical cohort not treated with rifampin (HR 0.11; 95%CI 0.01-0.84). None (0/14) of the patients in the prospective study developed hepatotoxicity. The outcome of staphylococcal PJI treated with D/R and rifampin-based regimens was better when compared with a historical cohort treated without rifampin.

AB - The aim of this study was to evaluate the efficacy and safety of rifampin for Staphylococcus aureus (SA) or coagulase negative staphylococci (CNS) prosthetic joint infection (PJI) treated with debridement and retention (D/R). We calculated the treatment failure cumulative incidence (TF) of a cohort of 101 patients with SA or CNS PJI treated with D/R and antimicrobial therapy. The effect of the use of a rifampin-based regimen was evaluated. Cox proportional hazards regression evaluated the association between treatment and time-to-TF controlling for the propensity to treat with rifampin and temporal confounders. Seven percent (1/14) of the prospective rifampin-treated patients, 32% (10/31) of the historical rifampin-treated patients and 38% (21/56) of the historical non-rifampin treated patients developed TF. After controlling for the propensity to treat with rifampin and American Society of Anesthesia scores, patients in the prospective cohort had a lower risk of TF compared to patients in the historical cohort not treated with rifampin (HR 0.11; 95%CI 0.01-0.84). None (0/14) of the patients in the prospective study developed hepatotoxicity. The outcome of staphylococcal PJI treated with D/R and rifampin-based regimens was better when compared with a historical cohort treated without rifampin.

UR - http://www.scopus.com/inward/record.url?scp=77955471874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955471874&partnerID=8YFLogxK

U2 - 10.1007/s10096-010-0952-9

DO - 10.1007/s10096-010-0952-9

M3 - Article

VL - 29

SP - 961

EP - 967

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

SN - 0934-9723

IS - 8

ER -